Cantoni Therapeutics

Developer of novel small molecule inhibitors targeting NNMT for cardiometabolic diseases

placeLeiden, South Holland, Netherlands calendar_todayFounded 2022 language cantonitx.nl

Social engagement

Social engagement: 775 social following, 8 posts in the last 12 months — below the industry typical range.

Investor mix

3 investors on record; lead investors include BOM.

Investor typeCountShare
Venture capital267%
Other / undisclosed133%

Recent activity

1 May 2026
Event
BioEquity Europe
2 Nov 2025
Event
Summer A fundraising activities
23 Oct 2025
Recognition
Coming soon